AASLD Adds Semaglutide to MASH Practice Guidance With NIT-Based Selection

This November 2025 AASLD update operationalizes semaglutide (Wegovy) for F2-F3 MASH, replacing biopsy-driven selection with noninvasive test thresholds and detailing a comprehensive GLP-1 safety-monitoring framework relevant to every dispensing and clinical pharmacist.

AASLD Practice GuidanceAmerican Association for the Study of Liver DiseasesMASHMASLDsemaglutideGLP-1 receptor agonistsnoninvasive fibrosis testing Gastroenterology / Hepatology

Background Information

Semaglutide offers new hope for MASH management with significant fibrosis improvement.

The updated AASLD guideline provides new insights on semaglutide use for metabolic dysfunction-associated steatohepatitis (MASH), emphasizing patient selection and safety monitoring. Semaglutide significantly improved MASH resolution (62.9% vs 34.3% placebo, p<0.001) and liver fibrosis reduction (36.8% vs 22.4% placebo, p<0.001). Guidelines recommend semaglutide for stage 2-3 fibrosis in MASH, highlighting its safety and efficacy but stressing careful monitoring for adverse effects. Semaglutide is effective for MASH with moderate-to-advanced fibrosis, offering a new therapeutic option.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM

Citation: Bansal MB, Patton H, Morgan TR, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology (Baltimore, Md.). 2026;83(5):1326-1340. doi:10.1097/HEP.0000000000001608

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →